Moreover, the combination of anti-CD24 and anti-CD47 monoclonal antibodies was shown to remarkably promote the phagocytosis of cancer cells by macrophages, thus suggesting a plausible synergistic antitumor effect from two classes of phagocytosis checkpoint inhibitors [196, 370]. This evidence concerns the gene CD47 and cancer.